SmartSensor Telemed voted Best Medtech Dealmaker at the 2012
We are pleased to announce that DiagnOx tenant SmartSensor telemed was voted Best Medtech Dealmaker at the 2012 Oxford Bioscience Network Annual Awards Dinner on September 11.
SmartSensor Telemed is developing an e-healthcare and telemedicine platform. The development of their first product, a home use Oral Glucose Tolerance Test, is already being supported by a Swiss pharmaceutical company.
The award recognises the innovative and entrepreneurial deal the company agreed with global pharmaceuticals company Novartisto support the development of a home-use Oral Glucose Tolerance Test (OGTT) for assessing all forms of diabetes.
Dave Hales from category sponsor Ernst & Young presented the award to SmartSensor telemed’s founder and CEO, James Jackson.
The competing short-listed companies for the award were Manchester based stem-cell science company Epistem Holdings Plc and Cambridge based drug delivery device company Oval Medical Technologies Ltd.
The awards dinner was held at the Ashmolean Museum in Oxford and celebrated the achievements and major success stories in UK the biotech, medtech and diagnostics sectors over the previous 12 months.